ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research

Sep 22, 2026

Competitive National Eye Institute funding provides external validation of ClearSight's proposed scientific program and supports a one-year investigation of a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.

DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC

Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence

DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.

The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.

Why this award matters

NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.

"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."

Patrick Smale, Co-founder and Chief Executive Officer

"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."

Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator

"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."

Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member

The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.

Important regulatory context

ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.

About ClearSight Therapeutics


ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.

NIH funding acknowledgment

Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Media contact

Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761

Contact
Patrick Smale
***@clearsighttx.com

Photos: (Click photo to enlarge)




Source: ClearSight Therapeutics, Inc.

Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source

Press release distribution by PRLog
MORE NEWS
The Car Expo and Lifestyle Edit are set to offer a high-octane and comprehensive lifestyle shopping destination at Singapore Expo this month
Oct 16, 2026
The Car Expo and Lifestyle Edit are set to offer a high-octane and comprehensive lifestyle shopping destination at Singapore Expo this month

The upsized Car Expo returns to Singapore Expo with more than 50 car brands, now with a tech and home lifestyle extension, plus great deals and prizes to take home!

Huawei MatePad Air hands-on: Great battery life and display in a slim, lightweight package
Oct 16, 2026
Huawei MatePad Air hands-on: Great battery life and display in a slim, lightweight package

The Huawei MatePad Air has a generous 12-inch display, but it’s only 5.3mm thin.

SK hynix showcases next-generation AI memory technologies beyond HBM
Oct 16, 2026
SK hynix showcases next-generation AI memory technologies beyond HBM

SK hynix said Friday that it has showcased its next-generation artificial intelligence (AI) memory technologies aimed at expanding the boundaries of AI infrastructure beyond conventional high-bandwidth memory (HBM). The company presented the technologies at the OCP Global Summit 2026, held in California from Tuesday to Thursday (local time). The summit is an annual conference organized by the Open Compute Project Foundation that brings together engineers and industry leaders. The Korean chip giant said it divided its exhibition space into two sections. The front section, dubbed the memory section, showcased the company's flagship products, while the larger rear section, called the system demo section, featured memory solutions designed to support next-generation server ecosystems. Kim Ho-sik, a senior vice president at SK hynix, introduced MARS (Memory-Centric AI Rack-Scale System), a disaggregated rack-scale architecture designed to coordinate computing and memory resources seamlessly. Kim highlighted progress in High Bandwidth Flash (HBF), a technology aimed at addressing the industry's

Ecosystem Roundup: Singapore’s always-on workers are performing to an empty room
Oct 16, 2026
Ecosystem Roundup: Singapore’s always-on workers are performing to an empty room

Singapore’s office workers answer a 10.47pm message within 90 seconds to prove their commitment. Their bosses barely notice. The Jobstreet by SEEK Singapore Workplace Culture Study 2026, which surveyed 600 employees and jobseekers and 200 hiring decision makers, finds that 63% of staff signal dedication by replying fast, a behaviour only 39% of employers value. […] The post Ecosystem Roundup: Singapore’s always-on workers are performing to an empty room appeared first on e27.

The US$82,000 Illusion: Why Bitcoin still trades like a traditional tech stock
Oct 16, 2026
The US$82,000 Illusion: Why Bitcoin still trades like a traditional tech stock

Bitcoin currently trades at US$82,231.14, reflecting a 0.65 per cent gain over the last 24 hours. This movement mirrors a broader 0.84 per cent rise in the total crypto market capitalisation. Having operated in this industry for over 15 years and advised on blockchain policy, I view this price action as a clear reflection of […] The post The US$82,000 Illusion: Why Bitcoin still trades like a traditional tech stock appeared first on e27.

Hong Kong builds a test track for robots that keep failing outside the lab
Oct 16, 2026
Hong Kong builds a test track for robots that keep failing outside the lab

Every humanoid robot looks brilliant in a launch video. The trouble begins on an ordinary weekday in a warehouse, when a parcel arrives in a shape nobody trained the machine for, a forklift reverses where it shouldn’t, and a worker strolls into its path while scrolling a phone. That messy gap between the lab and […] The post Hong Kong builds a test track for robots that keep failing outside the lab appeared first on e27.

Why a small Gulf currency matters for Partior’s Southeast Asian ambitions
Oct 16, 2026
Why a small Gulf currency matters for Partior’s Southeast Asian ambitions

The National Bank of Bahrain (NBB) has signed a memorandum of understanding with blockchain settlement network Partior to study whether the Bahraini dinar (BHD) can be settled on the Singaporean firm’s rails, with NBB acting as the currency’s settlement bank. Read the fine print and the ambition shrinks to its proper size. The MoU commits […] The post Why a small Gulf currency matters for Partior’s Southeast Asian ambitions appeared first on e27.

Your ESOP is a fundraising document.  Most founders treat it as a HR perk
Oct 16, 2026
Your ESOP is a fundraising document. Most founders treat it as a HR perk

Almost every founder I meet reaches the same conclusion at roughly the same moment. You cannot outbid a funded competitor on salary, so you give people a stake in the outcome instead. The logic is sound. Equity turns salary-limited hires into owners and aligns the people doing the work with the value they create. Then […] The post Your ESOP is a fundraising document. Most founders treat it as a HR perk appeared first on e27.

Employers are buying AI tools. Their managers are being left behind
Oct 16, 2026
Employers are buying AI tools. Their managers are being left behind

Thirty-seven per cent. Eleven per cent. Those two numbers, tucked deep inside Jobstreet by SEEK’s Singapore Workplace Culture Study 2026, may say more about the region’s productivity problem than any headline about AI or inflation. The first is the share of employees who try to manage workplace pressure by quietly drawing their own boundaries: muting […] The post Employers are buying AI tools. Their managers are being left behind appeared first on e27.

Before you use predictive AI, decide what decision it should change
Oct 16, 2026
Before you use predictive AI, decide what decision it should change

A lot of startup advice about predictive AI starts too early. It starts with the model, the tool, the data stack, or the dashboard. Those things matter, but they are not the first question. The first question is simpler: what decision should this prediction change? If a startup cannot answer that clearly, it is usually […] The post Before you use predictive AI, decide what decision it should change appeared first on e27.

'AI artists' perform improvised jazz at Jarasum Jazz Festival
Oct 16, 2026
'AI artists' perform improvised jazz at Jarasum Jazz Festival

Artificial intelligence (AI) models developed by a research team led by Korea Advanced Institute of Science and Technology (KAIST) professor Nam Ju-han made their debut at one of Korea’s leading jazz festivals, performing improvised jazz alongside human artists. According to the university Friday, the team showcased human-AI music collaboration technology that analyzes the flow of human performances in real time, allowing AI to take over performances or generate improvised accompaniment, during the 23rd Jarasum Jazz Festival, held in Gapyeong County, Gyeonggi Province, from Oct. 9 to 11. A total of 12 human jazz artists participated in the event, collaborating with AI in 26 pieces across 12 performances. The technology is different from existing music AI services as it enables collaboration with human musicians in jazz, a genre characterized by improvisation. Jazz musicians often change the tempo or create new melodies based on how they feel in the moment. Because the same piece can be performed differently each time, musicians must listen to one another and adjust their playing accord

DEFA cuts the cost of entry. Your architecture sets the cost of scale
Oct 16, 2026
DEFA cuts the cost of entry. Your architecture sets the cost of scale

Sit in the architecture review of almost any platform that has reached four ASEAN markets and the same diagram appears. One product on top. Underneath, four data stores, four payment integrations, four know-your-customer flows (the identity checks that onboard each user), and four sets of legal entities and directors. Adding Malaysia means adding a […] The post DEFA cuts the cost of entry. Your architecture sets the cost of scale appeared first on e27.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

About Us

Always dynamic, always updated, The Witness Daily ensures minute-by-minute update to the most pressing issues, curated specifically to cater to critical newsreaders of our time.

Copyright © 2015 - 2026 Redshift Daily. All Rights Reserved.